Paris, France

Emmanuel Conseiller

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2001-2018

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Emmanuel Conseiller: Innovator in Genomic Detection

Introduction

Emmanuel Conseiller is a prominent inventor based in Paris, France. He has made significant contributions to the field of genomic detection, particularly in methods related to cancer predisposition. With a total of 5 patents, his work has had a profound impact on genetic research and diagnostics.

Latest Patents

Among his latest patents is a method for the detection of sequence amplification in the BRCA1 locus. This innovative method focuses on identifying amplifications of sequences that are present at least twice in the BRCA1 locus, which can lead to a predisposition to diseases such as ovarian and breast cancer. Another notable patent involves a method for identifying or detecting genomic rearrangements in biological samples. This method utilizes specially designed sets of long and short probes to enhance resolution and simplify the visualization and detection of polynucleotide sequences. These advancements are crucial for assessing genomic rearrangements associated with various diseases, including cancer.

Career Highlights

Emmanuel Conseiller has worked with notable companies in the pharmaceutical and genomic sectors, including Aventis Pharma S.A. and Genomic Vision. His experience in these organizations has allowed him to develop and refine his innovative methods, contributing to advancements in genetic diagnostics.

Collaborations

Throughout his career, Emmanuel has collaborated with esteemed colleagues such as Laurent Bracco and Maurizio Ceppi. These partnerships have fostered a collaborative environment that has enhanced the development of his groundbreaking work.

Conclusion

Emmanuel Conseiller's contributions to genomic detection and cancer predisposition research are invaluable. His innovative methods and collaborations continue to shape the future of genetic diagnostics and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…